Human papillomavirus proteins as prospective therapeutic targets

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 55-65

  Pang, Chai Ling ^a   Thierry, Françoise ^b  

^a AGENCY FOR SCIENCE   (Singapore)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

Cervical cancer; HPV; Oncogenes; Therapeutic targets; Viral cycle

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; CAPSID PROTEIN L2; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; POLO LIKE KINASE; POLO LIKE KINASE 4; PROTEIN E2C; PROTEIN E4; PROTEIN E5; PROTEIN E58; PROTEIN E6; PROTEIN E7; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ARTICLE; DISEASE ASSOCIATION; DNA REPLICATION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION RISK; INTRACELLULAR SIGNALING; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRAL LIFE CYCLE; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS PARTICLE; WART VIRUS;

CELL TRANSFORMATION, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRULENCE FACTORS; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84875859545     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.11.002     Document Type: Article

References (142)

1. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
2. Arbyn M., Castellsague X., de Sanjose S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
4. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802.
5. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J Clin 2002, 2005(55):74-108.
6. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005, 32(Suppl. 1):S7-S15.
7. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67:6929-6936.
8. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257.
9. Day P.M., Pang Y.Y., Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012, 19:1075-1082.
10. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
11. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
12. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92:690-698.
13. Su J.H., Wu A., Scotney E., Ma B., Monie A., Hung C.F., et al. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 2010, 24:109-129.
14. Trimble C.L., Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 2009, 10:975-980.
15. Crum C.P., Barber S., Symbula M., Snyder K., Saleh A.M., Roche J.K. Coexpression of the human papillomavirus type 16 E4 and L1 open reading frames in early cervical neoplasia. Virology 1990, 178:238-246.
16. Maitland N.J., Conway S., Wilkinson N.S., Ramsdale J., Morris J.R., Sanders C.M., et al. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low-and high-grade cervical intraepithelial neoplasia. J Pathol 1998, 186:275-280.
17. Xue Y., Bellanger S., Zhang W., Lim D., Low J., Lunny D., et al. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res 2010, 70:5316-5325.
18. Ressler S., Scheiden R., Dreier K., Laich A., Muller-Holzner E., Pircher H., et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007, 13:7067-7072.
19. Meyers C., Mayer T.J., Ozbun M.A. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 1997, 71:7381-7386.
20. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 2009, 384:375-379.
21. Bellanger S., Tan C.L., Xue Y.Z., Teissier S., Thierry F. Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res 2011, 1:373-389.
22. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284.
23. Desaintes C., Demeret C. Control of papillomavirus DNA replication and transcription. Semin Cancer Biol 1996, 7:339-347.
24. Desaintes C., Demeret C., Goyat S., Yaniv M., Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997, 16:504-514.
25. Dowhanick J.J., McBride A.A., Howley P.M. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995, 69:7791-7799.
26. Goodwin E.C., Naeger L.K., Breiding D.E., Androphy E.J., DiMaio D. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol 1998, 72:3925-3934.
27. Hwang E.S., Riese D.J., Settleman J., Nilson L.A., Honig J., Flynn S., et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 1993, 67:3720-3729.
28. Teissier S., Ben Khalifa Y., Mori M., Pautier P., Desaintes C., Thierry F. A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells. J Virol 2007, 81:9368-9376.
29. Xue Y, Lim D, Zhi L, He P, Abastado JP, Thierry F. Loss of HPV16 E2 protein expression without disruption of the E2 ORF correlates with carcinogenic progression. Open Virol J, in press.
30. Herfs M., Yamamoto Y., Laury A., Wang X., Nucci M.R., McLaughlin-Drubin M.E., et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012, 109:10516-10521.
31. Bellanger S., Blachon S., Mechali F., Bonne-Andrea C., Thierry F. High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability. Cell Cycle 2005, 4:1608-1615.
32. Muller M., Jacob Y., Jones L., Weiss A., Brino L., Chantier T., et al. Large scale genotype comparison of human papillomavirus E2-host interaction networks provides new insights for e2 molecular functions. PLoS Pathog 2012, 8:e1002761.
33. Boner W., Morgan I.M. Novel cellular interacting partners of the human papillomavirus 16 transcription/replication factor E2. Virus Res 2002, 90:113-118.
34. Blachon S., Bellanger S., Demeret C., Thierry F. Nucleo-cytoplasmic shuttling of high risk human papillomavirus E2 proteins induces apoptosis. J Biol Chem 2005, 280:36088-36098.
35. Doorbar J., Ely S., Sterling J., McLean C., Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991, 352:824-827.
36. Doorbar J., Cubie H. Molecular basis for advances in cervical screening. Mol Diagn 2005, 9:129-142.
37. Davy C., McIntosh P., Jackson D.J., Sorathia R., Miell M., Wang Q., et al. A novel interaction between the human papillomavirus type 16 E2 and E1-E4 proteins leads to stabilization of E2. Virology 2009, 394:266-275.
38. Tan C.L., Gunaratne J., Lai D., Carthagena L., Wang Q., Xue Y.Z., et al. HPV-18 E2̂E4 chimera: 2 new spliced transcripts and proteins induced by keratinocyte differentiation. Virology 2012, 429:47-56.
39. You J., Croyle J.L., Nishimura A., Ozato K., Howley P.M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004, 117:349-360.
40. Thierry F., Demeret C. Direct activation of caspase 8 by the proapoptotic E2 protein of HPV18 independent of adaptor proteins. Cell Death Differ 2008, 15:1356-1363.
41. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
42. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384:324-334.
43. Thierry F., Yaniv M. The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J 1987, 6:3391-3397.
44. Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P., et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008, 68:307-313.
45. Goodwin E.C., DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 2000, 97:12513-12518.
46. Goodwin E.C., Yang E., Lee C.J., Lee H.W., DiMaio D., Hwang E.S. Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A 2000, 97:10978-10983.
47. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985, 314:111-114.
48. Rozenblatt-Rosen O., Deo R.C., Padi M., Adelmant G., Calderwood M.A., Rolland T., et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 2012, 487:491-495.
49. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
50. Huibregtse J.M., Scheffner M., Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993, 13:775-784.
51. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
52. Thomas M.C., Chiang C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005, 17:251-264.
53. Jha S., Vande Pol S., Banerjee N.S., Dutta A.B., Chow L.T., Dutta A. Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol Cell 2010, 38:700-711.
54. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999, 80(Pt 6):1513-1517.
55. Filippova M., Song H., Connolly J.L., Dermody T.S., Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002, 277:21730-21739.
56. Garnett T.O., Filippova M., Duerksen-Hughes P.J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006, 13:1915-1926.
57. Duerksen-Hughes P.J., Yang J., Schwartz S.B. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 1999, 264:55-65.
58. Filippova M., Johnson M.M., Bautista M., Filippov V., Fodor N., Tungteakkhun S.S., et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007, 81:4116-4129.
59. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 2006, 80:5301-5307.
60. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94:11612-11616.
61. Lee S.S., Weiss R.S., Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94:6670-6675.
62. Lee S.S., Glaunsinger B., Mantovani F., Banks L., Javier R.T. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 2000, 74:9680-9693.
63. Nakagawa S., Huibregtse J.M. Human Scribble (vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 2000, 20:8244-8253.
64. Watson R.A., Thomas M., Banks L., Roberts S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci 2003, 116:4925-4934.
65. Beaudenon S., Huibregtse J.M. HPV E6, E6AP and cervical cancer. BMC Biochem 2008, 9(Suppl. 1):S4.
66. Hoover A.C., Strand G.L., Nowicki P.N., Anderson M.E., Vermeer P.D., Klingelhutz A.J., et al. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009, 28:3960-3970.
67. Spanos W.C., Hoover A., Harris G.F., Wu S., Strand G.L., Anderson M.E., et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol 2008, 82:2493-2500.
68. Gewin L., Myers H., Kiyono T., Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004, 18:2269-2282.
69. Gao Q., Kumar A., Singh L., Huibregtse J.M., Beaudenon S., Srinivasan S., et al. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 2002, 62:3315-3321.
70. Degenhardt Y.Y., Silverstein S.J. Gps2, a protein partner for human papillomavirus E6 proteins. J Virol 2001, 75:151-160.
71. Kukimoto I., Aihara S., Yoshiike K., Kanda T. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein. Biochem Biophys Res Commun 1998, 249:258-262.
72. Kuhne C., Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 1998, 273:34302-34309.
73. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J.I., Caldecott K.W., et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002, 21:4741-4748.
74. Srivenugopal K.S., Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 2002, 21:5940-5945.
75. Ben Khalifa Y., Teissier S., Tan M.K., Phan Q.T., Daynac M., Wong W.Q., et al. The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63beta upon transformation. PLoS Pathog 2011, 7:e1002256.
76. Park J.S., Kim E.J., Lee J.Y., Sin H.S., Namkoong S.E., Um S.J. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 2001, 91:822-827.
77. Phelps W.C., Bagchi S., Barnes J.A., Raychaudhuri P., Kraus V., Münger K., et al. Analysis of transactivation by human papillomavirus type 16 E7 and Adenovirus 12S E1A suggests a common mechanism. J Virol 1991, 65:6922.
78. Klingelhutz A.J., Roman A. Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology 2012, 424:77-98.
79. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 2006, 21:665-678.
80. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 2007, 81:9737-9747.
81. Burgers W.A., Blanchon L., Pradhan S., de Launoit Y., Kouzarides T., Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26:1650-1655.
82. Caberg J.H., Hubert P.M., Begon D.Y., Herfs M.F., Roncarati P.J., Boniver J.J., et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008, 29:1441-1447.
83. Tasaki T., Mulder L.C., Iwamatsu A., Lee M.J., Davydov I.V., Varshavsky A., et al. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol Cell Biol 2005, 25:7120-7136.
84. DeMasi J., Chao M.C., Kumar A.S., Howley P.M. Bovine papillomavirus E7 oncoprotein inhibits anoikis. J Virol 2007, 81:9419-9425.
85. Huh K.W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., Munger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A 2005, 102:11492-11497.
86. Luscher-Firzlaff J.M., Westendorf J.M., Zwicker J., Burkhardt H., Henriksson M., Muller R., et al. Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation. Oncogene 1999, 18:5620-5630.
87. Hwang S.G., Lee D., Kim J., Seo T., Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem 2002, 277:2923-2930.
88. McLaughlin-Drubin M.E., Huh K.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol 2008, 82:8695-8705.
89. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999, 18:2449-2458.
90. Bodily J.M., Mehta K.P., Laimins L.A. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res 2011, 71:1187-1195.
91. McLaughlin-Drubin M.E., Crum C.P., Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A 2011, 108:2130-2135.
92. Duensing S., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002, 62:7075-7082.
93. Nguyen C.L., Munger K. Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J Virol 2009, 83:1700-1707.
94. Nguyen C.L., Eichwald C., Nibert M.L., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin. J Virol 2007, 81:13533-13543.
95. Korzeniewski N., Treat B., Duensing S. The HPV-16 E7 oncoprotein induces centriole multiplication through deregulation of Polo-like kinase 4 expression. Mol Cancer 2011, 10:61.
96. Maufort J.P., Williams S.M., Pitot H.C., Lambert P.F. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 2007, 67:6106-6112.
97. Genther S.M., Sterling S., Duensing S., Munger K., Sattler C., Lambert P.F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol 2003, 77:2832-2842.
98. Krawczyk E., Suprynowicz F.A., Liu X., Dai Y., Hartmann D.P., Hanover J., et al. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am J Pathol 2008, 173:682-688.
99. Conrad M., Bubb V.J., Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are mebrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 1993, 67:6170-6178.
100. Venuti A., Paolini F., Nasir L., Corteggio A., Roperto S., Campo M.S., et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011, 10:140.
101. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995, 69:3185-3192.
102. Crusius K., Auvinen E., Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997, 15:1437-1444.
103. Gu Z., Matlashewski G. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol 1995, 69:8051-8056.
104. Venuti A., Salani D., Poggiali F., Manni V., Bagnato A. The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth. Virology 1998, 248:1-5.
105. Tsao Y.P., Li L.Y., Tsai T.C., Chen S.L. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes. J Virol 1996, 70:7535-7539.
106. Pedroza-Saavedra A., Lam E.W., Esquivel-Guadarrama F., Gutierrez-Xicotencatl L. The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology 2010, 400:44-52.
107. Kabsch K., Alonso A. The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol 2002, 76:12162-12172.
108. Oh J.M., Kim S.H., Cho E.A., Song Y.S., Kim W.H., Juhnn Y.S. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 2010, 31:402-410.
109. Oh J.M., Kim S.H., Lee Y.I., Seo M., Kim S.Y., Song Y.S., et al. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009, 30:141-149.
110. Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J., et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci 2006, 63:930-938.
111. Li S., Labrecque S., Gauzzi M.C., Cuddihy A.R., Wong A.H., Pellegrini S., et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18:5727-5737.
112. Ronco L.V., Karpova A.Y., Vidal M., Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12:2061-2072.
113. Park J.S., Kim E.J., Kwon H.J., Hwang E.S., Namkoong S.E., Um S.J. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000, 275:6764-6769.
114. Um S.J., Rhyu J.W., Kim E.J., Jeon K.C., Hwang E.S., Park J.S. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 2002, 179:205-212.
115. Thompson D.A., Zacny V., Belinsky G.S., Classon M., Jones D.L., Schlegel R., et al. The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts. Oncogene 2001, 20:3629-3640.
116. Zhang B., Li P., Wang E., Brahmi Z., Dunn K.W., Blum J.S., et al. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology 2003, 310:100-108.
117. Miura S., Kawana K., Schust D.J., Fujii T., Yokoyama T., Iwasawa Y., et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol 2010, 84:11614-11623.
118. Boulabiar M., Boubaker S., Favre M., Demeret C. Keratinocyte sensitization to tumour necrosis factor-induced nuclear factor kappa B activation by the E2 regulatory protein of human papillomaviruses. J Gen Virol 2011, 92:2422-2427.
119. Stanley M.A. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 2012, 93:681-691.
120. Schuck S., Stenlund A. Mechanistic analysis of local ori melting and helicase assembly by the papillomavirus E1 protein. Mol Cell 2011, 43:776-787.
121. Sedman J., Stenlund A. The papillomavirus E1 protein forms a DNA-dependent hexameric complex with ATPase and DNA helicase activities. J Virol 1998, 72:6893-6897.
122. Blitz I.L., Laimins L.A. The 68-kilodalton E1 protein of bovine papillomavirus is a DNA binding phosphoprotein which associates with the E2 transcriptional activator in vitro. J Virol 1991, 65:649-656.
123. Sedman T., Sedman J., Stenlund A. Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus. J Virol 1997, 71:2887-2896.
124. Loo Y.M., Melendy T. Recruitment of replication protein A by the papillomavirus E1 protein and modulation by single-stranded DNA. J Virol 2004, 78:1605-1615.
125. MacPherson P., Thorner L., Parker L.M., Botchan M. The bovine papilloma virus E1 protein has ATPase activity essential to viral DNA replication and efficient transformation in cells. Virology 1994, 204:403-408.
126. Park P., Copeland W., Yang L., Wang T., Botchan M.R., Mohr I.J. The cellular DNA polymerase alpha-primase is required for papillomavirus DNA replication and associates with the viral E1 helicase. Proc Natl Acad Sci U S A 1994, 91:8700-8704.
127. Cote-Martin A., Moody C., Fradet-Turcotte A., D'Abramo C.M., Lehoux M., Joubert S., et al. Human papillomavirus E1 helicase interacts with the WD repeat protein p80 to promote maintenance of the viral genome in keratinocytes. J Virol 2008, 82:1271-1283.
128. Lehoux M., Fradet-Turcotte A., Lussier-Price M., Omichinski J.G., Archambault J. Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide. J Virol 2012, 86:3486-3500.
129. Skiadopoulos M.H., McBride A.A. Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. J Virol 1998, 72:2079-2088.
130. Massimi P., Pim D., Bertoli C., Bouvard V., Banks L. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 1999, 54:7748-7754.
131. Wu S.Y., Lee A.Y., Hou S.Y., Kemper J.K., Erdjument-Bromage H., Tempst P., et al. Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Dev 2006, 20:2383-2396.
132. Smith J.A., White E.A., Sowa M.E., Powell M.L., Ottinger M., Harper J.W., et al. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc Natl Acad Sci U S A 2010, 107:3752-3757.
133. Abbate E.A., Voitenleitner C., Botchan M.R. Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol Cell 2006, 24:877-889.
134. Bellanger S., Tan C.L., Nei W., He P.P., Thierry F. The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol 2010, 84:437-444.
135. Davy C.E., Jackson D.J., Wang Q., Raj K., Masterson P.J., Fenner N.F., et al. Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16. J Virol 2002, 76:9806-9818.
136. Raj K., Berguerand S., Southern S., Doorbar J., Beard P. E1 empty set E4 protein of human papillomavirus type 16 associates with mitochondria. J Virol 2004, 78:7199-7207.
137. Roberts S., Ashmole I., Gibson L.J., Rookes S.M., Barton G.J., Gallimore P.H. Mutational analysis of human papillomavirus E4 proteins: identification of structural features important in the formation of cytoplasmic E4/cytokeratin networks in epithelial cells. J Virol 1994, 68:6432-6445.
138. Khan J., Davy C.E., McIntosh P.B., Jackson D.J., Hinz S., Wang Q., et al. Role of calpain in the formation of human papillomavirus type 16 E1̂E4 amyloid fibers and reorganization of the keratin network. J Virol 2011, 85:9984-9997.
139. Dyson N., Howley P.M., Münger K., Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
140. Helt A.M., Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 2001, 75:6737-6747.
141. Fertey J., Ammermann I., Winkler M., Stoger R., Iftner T., Stubenrauch F. Interaction of the papillomavirus E8-E2C protein with the cellular CHD6 protein contributes to transcriptional repression. J Virol 2010, 84:9505-9515.
142. Powell M.L., Smith J.A., Sowa M.E., Harper J.W., Iftner T., Stubenrauch F., et al. NCoR1 mediates papillomavirus E8;E2C transcriptional repression. J Virol 2010, 84:4451-4460.